Peptides for Cognitive Enhancement

13 research peptides are currently studied for cognitive enhancement. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.

Evidence Rating: C

Category: Nootropic / Neuroprotective

Cerebrolysin is a brain-derived peptide complex consisting of low-molecular-weight neuropeptides (25%) and free amino acids (75%), produced by enzymatic hydrolysis of purified porcine brain proteins. All peptide fragments are below 10 kDa, allowing them to cross the blood-brain barrier. It is approved in over 40 countries (Europe, Asia, Russia) for stroke, traumatic brain injury, and dementia, but is NOT FDA-approved in the United States. Clinical evidence is mixed — some trials show benefit in stroke recovery while a 2023 Cochrane review found no clear mortality benefit.

Key claims: Improves stroke recovery; Cognitive improvement in dementia.

Evidence Rating: C

Category: Nootropic / Cognitive

Noopept (GVS-111, omberacetam) is a synthetic dipeptide derivative (N-phenylacetyl-L-prolylglycine ethyl ester, MW ~318.4 g/mol) developed at the Russian Academy of Sciences. It is not a true peptide but a peptidomimetic prodrug of the endogenous neuropeptide cycloprolylglycine. Noopept is approved in Russia for treatment of cognitive disorders of vascular and traumatic origin, but has not undergone rigorous clinical evaluation by Western regulatory standards.

Key claims: Cognitive enhancement in post-stroke and post-TBI patients; Neuroprotective effects.

Evidence Rating: C

Category: Nootropic / Anxiolytic

N-Acetyl Selank Amidate is a modified version of Selank with N-acetylation and C-amidation for increased metabolic stability. Base Selank is approved in Russia for anxiety and cognitive disorders. This modified form is popular for intranasal use in the research peptide community.

Key claims: Anxiety reduction; Longer duration vs standard Selank.

Evidence Rating: D

Category: Nootropic / Anxiolytic

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, MW ~751.89 g/mol) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a structural analogue of the immunomodulatory peptide tuftsin with an added Pro-Gly-Pro sequence for stability. Approved in Russia as an anxiolytic and nootropic nasal spray, it crosses the blood-brain barrier to enhance GABAergic neurotransmission, modulate monoamine systems, and regulate neuropeptide Y signaling. A 2008 study of 62 patients with GAD showed Selank comparable to medazepam for anxiety reduction but with no sedation, cognitive impairment, or dependence risk. Half-life is approximately 2-10 minutes.

Key claims: Reduces anxiety without sedation; Enhances cognitive function.

Evidence Rating: D

Category: Nootropic / Neuroprotective

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from adrenocorticotropic hormone (ACTH) fragment 4-10, with an added Pro-Gly-Pro sequence for metabolic stability. Molecular weight is approximately 813.88 g/mol (formula C37H51N9O10S). Discovered in Russia during the 1980s as part of government-funded neuropeptide research, it is approved in Russia and Ukraine for the treatment of ischemic stroke, cognitive disorders, encephalopathy, and optic nerve atrophy. Despite its ACTH origin, Semax does not activate adrenal corticosteroid production, acting selectively on brain-specific pathways.

Key claims: Neuroprotective in stroke; Enhances memory and cognitive function.

Evidence Rating: D

Category: Metabolic / Mitochondrial

Humanin is a 21-24 amino acid mitochondria-derived peptide (MDP) encoded by the MT-RNR2 gene in mitochondrial DNA. It was originally discovered in 2001 for its ability to protect neurons from Alzheimer's disease-related toxicity. Since then, it has been found to have broad cytoprotective, anti-inflammatory, anti-apoptotic, and metabolic effects. Circulating humanin levels decline with age and correlate with longevity in centenarian studies.

Key claims: Neuroprotection against Alzheimer's toxicity; Cardioprotection.

Evidence Rating: D

Category: Cognitive / Nootropic

Adamax is a synthetic derivative of Semax featuring an adamantane moiety that enhances blood-brain barrier (BBB) penetration and extends its half-life. Like Semax, it is derived from the ACTH(4-10) fragment but with additional N-acetyl and C-terminal adamantyl modifications. It is proposed to increase BDNF expression more potently than standard Semax and may have stronger nootropic and neuroprotective effects. No human clinical trials exist; all evidence is preclinical or anecdotal from self-experimenters.

Key claims: More potent than Semax for BDNF elevation; Enhances cognitive function and memory.

Evidence Rating: D

Category: Cognitive / Neuroprotection

Neuroxelin is a synthetic neuroprotective peptide proposed to modulate NMDA receptor activity and downregulate excessive microglial activation. It is theorized to protect neurons from excitotoxic damage while promoting synaptic plasticity. No peer-reviewed clinical trials or substantial preclinical publications exist; evidence is limited to vendor literature and preliminary in vitro data. It represents one of many novel neuropeptides marketed to the biohacking community without robust scientific validation.

Key claims: Neuroprotective against excitotoxicity; Reduces neuroinflammation.

Evidence Rating: D

Category: Neuroprotection / Research

FGL(S) is a synthetic peptide derived from the neural cell adhesion molecule (NCAM) that directly activates the fibroblast growth factor receptor (FGFR). It promotes neurite outgrowth, neuronal survival, and synaptic plasticity in preclinical models.

Key claims: Cognitive enhancement; Neuroprotection.

Evidence Rating: D

Category: Nootropic / Neurogenesis

P21 is a synthetic peptide derived from the active region of Ciliary Neurotrophic Factor (CNTF) that promotes hippocampal neurogenesis without the immunogenic side effects of full-length CNTF. It was developed to cross the blood-brain barrier and stimulate brain-derived neurotrophic factor (BDNF) release. Preclinical studies in Alzheimer's disease mouse models showed improved spatial memory and increased neurogenesis. It has become popular in the nootropics community but lacks human clinical data.

Key claims: Promotes hippocampal neurogenesis; Improves spatial learning and memory.

Evidence Rating: D

Category: Nootropic / Dopaminergic

9-Me-BC (9-Methyl-β-carboline) is a heterocyclic amine from the β-carboline family that has shown dopaminergic neurotrophic properties in preclinical studies. It is not a peptide but appears in peptide vendor catalogs and nootropic databases. In vitro and rodent studies suggest it promotes dopaminergic neuron growth and differentiation, upregulates tyrosine hydroxylase, and has anti-inflammatory effects in the brain. It has gained popularity in nootropic communities but carries significant safety unknowns, including potential phototoxicity and MAO inhibition.

Key claims: Promotes dopaminergic neuron growth; Improves cognitive function.

Evidence Rating: F

Category: Nootropic / Cognitive

Dihexa (PNB-0408) is a synthetic small molecule derived from angiotensin IV, developed at Washington State University by the Harding lab. It is a hepatocyte growth factor (HGF) mimetic that activates HGF/c-Met signaling in the brain, promoting synaptogenesis, neuroplasticity, and neuronal survival. Unlike large HGF proteins, Dihexa has good oral bioavailability and crosses the blood-brain barrier. In APP/PS1 Alzheimer's model mice, Dihexa activated the PI3K/AKT pathway, reduced neuroinflammation, and rescued cognitive impairment. It has also shown promise for peripheral nerve regeneration and protection against chemical ototoxicity. No human clinical trials exist.

Key claims: Rescues cognitive impairment in Alzheimer's model; Promotes peripheral nerve regeneration.